A carregar...
Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
BACKGROUND: Indacaterol 27.5 µg/glycopyrrolate 15.6 µg (IND/GLY 27.5/15.6 µg) inhalation powder, a twice-daily, fixed-dose combination of a long-acting beta2-agonist (LABA) and a long-acting antimuscarinic antagonist (LAMA), is indicated in the US for long-term maintenance treatment of airflow obstr...
Na minha lista:
| Publicado no: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6276826/ https://ncbi.nlm.nih.gov/pubmed/30568438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S177097 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|